1. CDER/CBER, FDA, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, Guid. Ind. (2015).
2. Characterization of biopharmaceuticals by NMR spectroscopy;Wishart;TrAC – Trends Anal. Chem.,2013
3. European Medicines Agency, Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins As Active Substance: Quality Issues, London, 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf.
4. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars;Berkowitz;Nat. Rev. Drug Discov.,2013
5. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications;Wei;Drug Discov. Today,2014